Trial reportEndocrinology, diabetes & metabolism2025
The Comparison of the Effect of Adding Empagliflozin to the Medication Regimen on Peripheral Neuropathy in Patients With Type II Diabetes: A Double Blind Randomised Clinical Trial.
Trial report in Endocrinology, diabetes & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Comparison of the Effect of Adding Empagliflozin to the Medication Regimen on Peripheral Neuropathy in Patients With Type II Diabetes: A Double Blind Randomised Clinical Trial.Endocrinology, diabetes & metabolism · 2025Trial
- Complex Contributions of Methylglyoxal to Pain, Axon Degeneration, and Diabetic Peripheral Neuropathy.Journal of neurochemistry · 2026Review
- Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.Diabetology & metabolic syndrome · 2026Review
- Bioenergetic failure in diabetic peripheral neuropathy: from glucotoxicity to multidimensional metabolic imbalance.Journal of neurology · 2026Review
- Targeting Oxidative Stress and Mitochondrial Dysfunction in Diabetic Neuropathy: Mechanisms and Therapeutic Opportunities.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetes is the common metabolic disorder. Empagliflozin is a new medication that acts as a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It promotes increased glucose excretion through urine, which helps improve blood sugar control, enhances glucose metabolism, and reduces glucotoxicity and insulin resistance. This study aimed to investigate and compare the effects of adding empagliflozin to a medication regimen on peripheral neuropathy in diabetes. MATERIALS AND
methodsThis study involved 50 patients with diabetic neuropathy, confirmed by the Michigan Neuropathy Screening Instrument, who were randomly assigned to two groups. The control group continued their previous medication regimen with a placebo, while the treatment group added 10 mg of empagliflozin daily to their existing regimen. At the start of the study, fasting blood glucose, haemoglobin A1c, serum creatinine levels and electrophysiological findings (including amplitude, latency and nerve conduction velocity) were assessed for all patients. These parameters were re-evaluated at the end of the 20-week intervention, and the results were analysed using statistical software.
resultsAt the end of the study, there was a significant reduction in both haemoglobin A1c and fasting blood glucose levels in the treatment group. Serum creatinine levels also significantly decreased. eGFR (estimated glomerular filtration rate) increased in the treatment group. In the Michigan Neuropathy Screening Instrument, the oral test score improved in the treatment group, but no significant difference was observed in the clinical examination scores. Additionally, electrophysiological testing showed a significant improvement in nerve conduction velocity in the treatment group. Latency also decreased in the treatment group, but no significant difference was observed in amplitude between the two groups.
conclusionEmpagliflozin reduces blood glucose levels and improves kidney filtration function. It also enhances clinical symptoms and nerve conduction velocity in patients with diabetic neuropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.